相关实验视频
Updated: Sep 11, 2025

05:51
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
13.3K
对动脉样硬化心血管疾病中的炎症途径和免疫调节的系统性审查
Qian Wang1, Yi-Xuan Sui2, Le-Tong Zhang3
1Cardiovascular Department, The Third Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun, China.
The American journal of cardiology
|August 16, 2025
概括
向性抗炎疗法,如互乐金-1β抑制剂和胆固醇,在预防超出脂质降低之外的心血管事件方面表现有前途. 科尔奇辛提供了一致的益处,即使炎症标志物较低.
科学领域:
- 心血管医学 心血管医学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症在动脉样硬化心血管疾病 (ASCVD) 中起着关键作用.
- 免疫调节提供了超越ASCVD传统降脂疗法的潜在好处.
- 许多ASCVD患者的残留炎症风险仍然存在,尽管脂质管理最佳.
研究的目的:
- 系统地审查ASCVD的炎症途径和免疫调节疗法.
- 评估针对性抗炎疗法在减少心血管事件方面的疗效.
- 根据炎症标志物确定ASCVD预防的有希望的治疗策略.
主要方法:
- 对57项研究 (2000-2025) 进行符合PRISMA 2020标准的系统审查.
- 包括随机试验,观察队列,生物标记分析和遗传研究.
- 对抗炎症药物的评估,这些药物准了像白蛋白-1β (IL-1β) 和白蛋白-6 (IL-6) 这样的途径.
主要成果:
- 干白素-1β (IL-1β) 抑制剂和胆固醇持续减少主要心血管事件.
- 科尔奇辛甚至在患有低C反应蛋白 (CRP) 水平的患者中也显示出有效性.
- 干白素-6 (IL-6) 抑制剂有效抑制生物标志物,但结果数据尚未公布.
- 甲托雷克萨特没有显示出临床益处,而生物药物感染风险很小.
结论:
- 抗炎疗法是ASCVD预防的有前途的辅助药物,特别是对于残留炎症风险的患者.
- 科尔奇辛表现出最强有力的证据,以减少心血管事件.
- 需要进一步的研究来确定IL-6抑制的作用和个性化抗炎治疗策略在ASCVD.
相关概念视频
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Atherosclerosis I: Introduction
82
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
82
Inflammatory Response
7.2K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
7.2K
Psychoneuroimmunology: Cardiovascular Disease
78
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
78
Inflammation
55.1K
Overview
55.1K
Coronary Artery Disease II: Pathophysiology
35
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
35

